Demeter Bio raises £26.6k for sustainable biopolymer development

Developing high-performance biopolymers from renewable sources is the core focus of Demeter Bio, a London-based biotechnology firm. The company aims to provide bio-based alternatives for the materials industry, creating products that are intended to be both environmentally friendly and commercially scalable. Its work involves the manufacture of chemical products and dedicated research into biotechnology applications.

The company recently secured £26.6k in new funding, resulting in an estimated post-money valuation of £896.7k. This latest capital injection follows several previous funding rounds. In February 2026, the business raised £108k at a valuation of £3.1m. During April 2025, Demeter Bio completed two separate funding events, raising £143.7k at a £2.2m valuation and £1.1m at a £5m valuation.

Founded in January 2025, Demeter Bio operates with a small team. Financial records for the year ended 31 January 2026 indicate the company has three employees, while recent social media data suggests a headcount of four. The business is headquartered in London and maintains its primary digital presence at demeter-bio.com.

The latest funding documentation was filed in May 2026, following an allotment of shares in April 2026. These funds support the company's ongoing efforts to replace traditional chemical-based materials with sustainable alternatives through its research and development facility.